oral vaccines for the aquaculture industry

about us


VakSea’s first product is an oral vaccine to protect against Viral Nervous Necrosis (VNN), which affects over 40 species of cultured marine fish worldwide. VakSea’s products can be fed directly to fish, eliminating the need for expensive, labor intensive, and invasive injection vaccines


Every year deadly disease outbreaks cause millions of dollars in economic losses for the $150 billion aquaculture industry. VakSea seeks to protect high-value fish species from disease, focusing first on European seabass, a $1.5 billion industry that operates primarily in the Mediterranean region


VakSea’s proprietary vaccine technology was developed at the University of Maryland Baltimore County (UMBC) in the lab of Dr. Vik Vakharia beginning in 2014. VakSea filed a provisional patent application in 2016

Our team

The VakSea team has extensive experience inventing animal health vaccines and taking early-stage technologies from concept to commercial product
Uploaded image

Dr. Ken Malone

Executive Chairman
Ken is a serial entrepreneur with 25 years of experience running technology-based companies. He has commercialized hundreds of products in advanced materials and life sciences and brings a broad experience base in business operations, IP management, M&A, and government affairs.
Uploaded image

Dr. Vik Vakharia

Chief Scientific Officer
Vik is a VLP vaccine expert with 30 years of research experience. He has successfully developed and licensed two poultry vaccines to large animal health companies. He has authored 89 publications and is an inventor on 15 U.S. and 27 foreign patents.
Uploaded image

Mihir Pershad

Chief Operations Officer
Mihir is a business development and operations professional who has supported the operations, business development, and fundraising of several early-stage biotechnology companies. Mihir has a diverse background that includes medical device startups and biomedical research.

Contact us